|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Cytokinetics, Inc.
| | | Phone: | (650) 624-3000 | Fax: | (650) 624-3010 | Year Established: | 1997 | Employees: | 83 | Ticker: | CYTK | Exchange: | NASDAQ | Main Contact: | Robert Blum, President & CEO | | Other Contacts: | Caryn G. McDowell, J.D., General Counsel Elisabeth A. Schnieders, Ph.D., Senior VP, Business Development Bradley P. Morgan, Ph.D., Senior VP, Drug Discovery & Early Development Andrew A. Wolff, M.D., Senior VP, & CMO Fady I. Malik, M.D., Ph.D., FACC, Executive VP, R&D Bonnie A. Charpentier, Ph.D., Senior VP, PreclinicalRegulatory Affairs and Compliance Sharon Barbari, Executive VP, Finance & CFO
| | Company Description | Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle troponin activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics retains the right to develop and commercialize tirasemtiv, subject to an option held by Astellas Pharma Inc. Cytokinetics is also collaborating with Astellas to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure. Amgen holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics' specified development and commercialization participation rights. | |
|
|
|
|
|